Year: 2025
Rapid Alert: CRACKDOWN AGAINST FALSIFIED / SPURIOUS DRUGS
Rapid Alert
| DRAP Alert No | No I/S/03-25-28 |
| Action Date | 5th March, 2025 |
| Target Audience | 1. Regulatory Field Force of DRAP and Provincial Drug Control departments. 2. Healthcare Professionals 3. Pharmacies and medical stores |
| Problem Statement | Directorate of Drug Control Punjab (DDCP) has informed the Drug Regulatory Authority of Pakistan that the samples of the below mentioned products have been declared ‘Spurious’. |
The product identification details are as under: –
Therapeutic Good Affected:-
| Product | Batch No* | Mfg Date | Exp. Date | Manufacturer Name (as per label) | Remarks |
| Syrup Carenol 60mL Each 5ml contains: Ammonium chloride 125mg, Sodium Citrate 55mg, Chlorpheniramine maleate 2.5mg Reg. No. 026907 | CL-036 | Purported to be manufactured by Well Care Pharmaceuticals, A/7, P.S.I.E. Sargodha-Pakistan. | ‘Spurious’ as per Drugs Act 1976, section 3(z-b) (i) and ‘Misbranded’ as per section 39(s)(vi). | ||
| Powder for Inj. 2Sum 2g Sterile powder of Cefoperazone sodium eq. to Cefoperazone 1g, Sterile powder for sulbactam sodium eq. to Sulbactum 1g per vial Reg. No. 071447 | APK072 | Purported to be manufactured by Healthtek (Pvt) Ltd, Plot No. 14, Sector 19, Korangi Industrial Area Karachi -Pakistan. | Spurious’ as per Drugs Act 1976, section 3(z-b) (i) & (ii) and ‘Adulterated’ as per section 3(s)(iv) and ‘Substandard’ on the basis of Sterility. |
| Risk Statement | Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences. |
| Action Initiated | The Regulatory Field Force has been directed to conduct surveillance activities to confiscate the abovementioned Un-Registered/falsified products. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation. |
| Advice for Healthcare Professionals | DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link. |
| Advice for Consumers | Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt. |
Recall Alert: SUBSTANDARD PRODUCTS DECLARED BY PROVINCIAL DRUG TESTING LABORATORIES.
Recall Alert
| DRAP Alert No | No I/S/03-25-26 |
| Action Date | 4th March, 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Directorate of Drugs Control (DDC) Punjab and Senior Drug Inspector ICT Islamabad has informed DRAP that samples below product has been reported substandard due to presence of impurities by Drug Testing Laboratory (DTL) Lahore and Rawalpindi: |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
Ame-Pin injection 2ml | Tramadol HCl 100mg | TD-038 | Ameer Pharma (Pvt.) Ltd., 23 KM, Sheikhupura road, Lahore |
| Aqua-P Injection | Sterile Water For Injection | P-665 | Ipram International, Plot No. 26, SS-3, NIZ, Rawat Islamabad |
| Flagyl Infusion | Metronidazole 500mg | AD460 | Sanofi-Aventis Pakistan Ltd., Plot No. 23, Sector 22, KIA, Karachi |
| Metroin Infusion | Metronidazole 500mg | MT24-103 | Saturn Pharmaceuticals, 23Km,Thokar-Raiwind Rd, Lahore |
| Euro-Flow Cannula | IV Cannula | 24/87 | Euromed for Medical Industries SAE Cairo Egypt |
| Rudazole Injection | Metronidazole 500mg | RD-044 | Rukha Pharmaceutical & Laboratories, 537-D&E Sundar Industrial Estate Lahore |
| Safemed Injection | Metronidazole 500mg | S-699 | Ahad Intl., Pharmaceutical, 13KM Gomal Uni, Multan Road, DI Khan |
| Pulmowell 120ml syrup | (Ammonium Chloride 30mg, Liquorice Ext. 50mg, Aniseed Oil 2.6ml) | PLW-001 | Vital Phyto Parma (Pvt.) Ltd., 7 KM from GT Road, Sohawa Chakwal Road, Rawalpindi |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |
Recall Alert: Substandard Products Declared By Provincial Drug Testing Laboratories:
Recall Alert
| DRAP Alert No | No I/S/03-25-27 |
| Action Date | 4th March, 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Directorate of Drug Control (DDC) Punjab has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been reported as ‘Substandard’. |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
| Aqua-P Injection | Sterile Water For Injection | P-665 | Ipram International, Plot No. 26, SS-3, NIZ, Rawat Islamabad |
| Injection Neocobal 1 ml Reg. No. 071447 | Mecobalamin 0.5mg/ml | S-2216 | M/s. Pulse Pharmaceuticals (Pvt.) Ltd. Sua Aasil, Raiwind Road, Lahore – Pakistan |
| Syrup Antimin 60ml Reg. No. 025951 | Each 5ml contains: Loratadine …..5mg | 063 | M/s. Shaigan Pharmaceuticals (Pvt) Ltd, 14-Km, Adyala Road, Rawalpindi – Pakistan |
| Injection Cara-Lac Reg. No. 054997 | Ketorolac Tromethamine 30mg/mL | 24J013 | M/s. Caraway Pharmaceuticals, Plot 12, St. N-3, National Industrial Zone (RCCI), Rawat, Islamabad. |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |
Rapid Alert: Presence of Unregistered Tramadol Formulations in the Market
Rapid Alert
| DRAP Alert No | No I/S/02-25-25 |
| Action Date | 27th February, 2025 |
| Target Audience | 1. Regulatory Field Force. 2. Therapeutic Goods Industry 3. Manufactures of Oral liquid preparations 4. Healthcare professionals |
| Problem Statement | The Federal Government Analyst, CDL, Karachi has notified the Drug Regulatory Authority of Pakistan that samples of the following products, seized by Customs, have been declared ‘Unregistered’ (falsified). The labels of these samples claim ‘Tramadol hydrochloride’ which has been confirmed by the test reports. Moreover, the labels do not provide any information regarding the manufacturer. The details of the reports are as below: |
The product identification details are as under: –
Therapeutic Good Affected:-
| Product | Batch No* | Mfg Date | Exp. Date | Manufacturer Name (as per label) | Remarks |
| Tramaking 225 Tablets | TM-044 | 03-2023 | 03-2026 | – | Un-Registered (Falsified) |
| New Tramadol 225 Tablets | TRD2015 | 02-2022 | 02-2027 | – | Un-Registered (Falsified) |
| TramaKing 250 Capsule | TKC2001 | 03-2022 | 03-2027 | – | Un-Registered (Falsified) |
| New Royal 225mg Tablets | TM-037 | 04-2023 | 04-2026 | – | Un-Registered (Falsified) |
| Tamral-250 Tablets | 243 | NIL | 03-2026 | – | Un-Registered (Falsified) |
| Tramaking Mega 225 Tablets | TRD2002 | 05-2022 | 05-2027 | – | Un-Registered (Falsified) |
| TramaKing 250 Tablets | TRK2001 | 03-2022 | 03-2027 | – | Un-Registered (Falsified) |
| Risk Statement | Falsified products having no identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences. |
| Action Initiated | The Regulatory Field Force has been directed to conduct surveillance activities to confiscate the abovementioned Un-Registered/falsified products. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation. |
| Advice for Healthcare Professionals | DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link. |
| Advice for Consumers | Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt. |
Minutes of the 344th Meeting of the Registration Board Held on 31st December, 2024 to 02nd January, 2025
The Drug Registration Board convened its 344th meeting on December 31st, 2024 to February, 20252 in the Committee Room of the Drug Regulatory Authority of Pakistan, Prime Minister’s National Health Complex, Park Road, Islamabad. The minutes of the meeting are hereby circulated for the information of all stakeholders.
Recall Alert: Recall of Substandard Floonix Injection (Batch # Inj-175) Manufactured by M/s Kayans Pharmaceuticals, Islamabad
Recall Alert
| DRAP Alert No | No I/S/02-25-24 |
| Action Date | 25th February 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Federal Government Analyst, Central Drugs Laboratory Karachi vide test/analysis No. IP-12-24-000101 dated 13-02-2025, has declared the sample of Floonix Injection (Batch # INJ-175), manufactured by M/s Kayans Pharmaceuticals, Islamabad, as ‘Substandard’. Details of test/analysis report are given as under:. |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
Floonix Injection For Veterinary use only. Reg. No. 112247 | Flunixin 50mg/ml | No: INJ-175 Mfg date: 11-2024 Expiry date: 11-2026 | M/s. Kayans Pharmaceuticals. Islamabad |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |
Rapid Alert: CONTAMINATED PROPYLENE GLYCOL (BATCH # A803S96G46) PURPOTEDLY MANUFACTURED BY M/S. DOW CHEMICAL PACIFIC (SINGAPORE) PRIVATE LIMITED.
Rapid Alert
| DRAP Alert No | No I/S/02-25-23 |
| Action Date | 25th February, 2025 |
| Target Audience | 1. Regulatory Field Force. 2. Therapeutic Goods industry 3. Manufactures of Oral liquid preparations 4. Healthcare professionals |
| Problem Statement | Federal Government Analyst, Central Drugs Laboratory Karachi vide test/analysis No. RM-1-25-000007 dated 20-02-2025, has declared the sample of Propylene glycol (Raw material) as ‘Substandard’ sent to CDL Karachi by the licensed pharmaceutical manufacturer in compliance to advisory issued by DRAP vide No. 03-41/2023-QC dated 01-12-2023. Details of test/analysis report are given as under: |
The product identification details are as under: –
Therapeutic Good Affected:-
| Product | Batch No* | Mfg Date | Exp. Date | Manufacturer Name (as per label) | Remarks |
| Propylene Glycol (Raw material) | A803S96G46 | 22-May-2023 | 21-May-2025 | M/s. Dow Chemical Pacific (Singapore) Private Limited | The sample is declared substandard due to conatmination of Ethylene Glycol. |
| Risk Statement | Di-Ethylene glycol (DEG) and Ethylene Glycol (EG) contaminated Propylene Glycol (PG) when used in oral liquid preparations can lead to serious health risks. When ingested, EG and DEG are converted into toxic metabolites that can affect the central nervous system and heart. Moreover, it can also cause kidney damage which may lead to fatal consequences. |
| Action Initiated | The Regulatory Field Force has directed to take increase surveillance for identification of above mentioned contaminated batch of Propylene Glycol in the market and is investigating the entire supply chain of this batch. The Regulatory Field Force has also been instructed to seize all oral preparations manufactured using the same batch of propylene glycol if found in the market. |
| Advice for Therapeutic Goods Manufacturers | Manufacturers of therapeutic goods are required to follow these instructions: 1. Recall Products: If any batch was manufactured using the same lot of Propylene Glycol that has been identified as contaminated, all finished products from local and export markets should be recalled. 2. Hold Other Batches: All finished products manufactured from the same lot of propylene glycol should be kept on hold. These products should be tested for EG/DEG contamination before releasing them into the supply chain. 3. Screen Raw Materials: Before using them in the manufacturing of oral liquid preparations, all raw materials should be screened for contamination with EG and DEG. 4. Compliance: Ensure compliance with all directives issued by DRAP to safeguard public health from contaminated products. 5. Follow Guidelines: Adhere to the pharmacopoeia monograph and WHO guidelines for testing EG/DEG in oral liquid preparations during the analysis of both raw materials and finished products. Our utmost priority is public safety. DRAP is committed to supporting the industry in maintaining rigorous quality control and testing procedures to prevent any potential harm caused by contaminated products. |
| Advice for Healthcare Professionals | DRAP requests healthcare professionals to stay updated with advisories and recalls. Patients should be educated about the risks and symptoms of EG toxicity. Close monitoring of patients using the affected products is crucial, and any adverse events should be reported to National or Provincial pharmacovigilance centres. -Adverse Drug Reactions (ADR) or quality problems experienced with the use of these products shall be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | Consumers should stay informed about the latest advisories and recalls from DRAP. If they have experienced any problem or unusual symptoms after using oral liquid preparations, seek medical attention immediately and report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt. |
Recall Alert: Voluntary Recall of all Batches of Lacolep Injection 10mg/ml Manufactured by M/s Hilton Pharma, Karachi.
Recall Alert
| DRAP Alert No | No I/S/02-25-22 |
| Action Date | 25th February 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | The firm M/s Hilton Pharma (Pvt) Ltd, Karachi, has informed Drug Regulatory Authority of Pakistan regarding voluntary recall of all marketed batches of Lacolep Injection 10mg/ml (Reg # 076086), due to the concerns regarding deviations in the quality parameters of certain batches of the aforementioned drug. In connection with this, the firm has published a public notice in the leading newspaper, The News-Jang, advising all distributors and dealers to return their stocks in hand to their nearest distributors and/or directly to the company. |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
Lacolep Injection 10mg/mL Reg. No. 076086 | Lacosamide | All marketed batches | M/s. Hilton Pharma Pvt. Ltd. Plot 13 & 14, Sector 15, Korangi Industrial Area, Karachi. |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |
Recall Alert: Substandard Products Declared By Provincial Drug Testing Laboratories.
Recall Alert
| DRAP Alert No | No I/S/02-25-21 |
| Action Date | 20th February 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Directorate of Drug Control (DDC) Punjab has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been reported as ‘Substandard’. |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
| Infusion Safemed 100mL Reg. No. 045824 | (Metronidazole 500mg /100ml) | Batch No. S-790-A | M/s. Ahad International Pharmaceuticals Ltd. 13-Km, Gomal University, Multan Road, Dera Ismail Khan |
| Syrup Resfyl 60mL Reg. No. 057214 | Each 5 mL contains: Acefylline Piperazine 45mg Diphenhydramine HCl 8mg | Batch No. 4A009 | M/s. Rasco Pharma, 5.5-Km, Raiwind Road, Lahore. |
| Sterile Water for Injection Reg. No. 024854 | Sterile Water for Injection | 224 | M/s. Pharmedic Labs (Pvt) Ltd, 16-Km Multan Road, Lahore. |
| Injection Ame-Pin Reg. No. 065943 | Tramdol HCl 100mg/2mL | TD-038 | M/s. Ameer Pharma (Pvt) Ltd, 23-Km, Sheikhupura Road, Lahore. |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |